Latest news and press releases about BioAtla, Inc. (BCAB): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer.
Price
| Price | $1.74 |
| Market Cap | $3M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -0.08 |
| EV / EBITDA | -0.25 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 89.25% |
| Return on Invested Capital | 318.00% |
| Return on Assets | -330.89% |
| Gross Margin | -4.15% |
| Operating Margin | -372.06% |
| Net Margin | -370.05% |
Related companies: ANVS · BTAI · CELU · EVAX · GBIO · MRSN · MURA
Explore sector: Healthcare · Biotechnology
More sections of BCAB: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks